Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study.

B Pistilli, K Jhaveri, S-A Im, S Pernas, M De Laurentiis, S Wang, N Martínez Jañez, G Borges, D W Cescon, M Hattori, Y-S Lu, E Hamilton, J Tsurutani, K Kalinsky, P E Rubini Liedke